Jagsonpal Pharma Buys 85% Stake in Hospital Segment

Jagsonpal Pharmaceuticals Ltd announced on June 29, 2026, that it has entered into an agreement to acquire 85% of Aequitas Healthcare Private Ltd. This strategic move signifies Jagsonpal's entry into the hospital segment, aligning with its long-term goal of enhancing its presence within India's expanding healthcare sector.

The acquisition consideration is ₹20.8 crore for the 85% stake, to be funded through internal accruals. The transaction is anticipated to conclude by July 15, 2026, and does not require governmental or regulatory approvals. Post-acquisition, Jagsonpal will control Aequitas Healthcare, while the existing directors will retain a 15% stake.

Jagsonpal's Managing Director, Manish Gupta, stated that the acquisition provides a ready platform in the hospital segment, which represents 10% of pharmaceutical industry sales and is experiencing rapid growth. He believes Jagsonpal's brands will benefit from Aequitas's strong institutional relationships.

Amrut Medhekar, Chief Operating Officer, described the transaction as a "structurally transformative pivot," moving Jagsonpal from a retail prescription model to an omnichannel specialty healthcare business. This move is intended to unlock value through operational excellence and patient-centric growth.